Mitchell E Reff

USPTO Granted Patents = 25 (Patent Applications = 1)

Average Co-Inventor Count = 2.6

ph-index = 15

Forward Citations = 1,802(Granted Patents)

Company Filing History:

9 out of 37

Idec Pharmaceuticals Corporation

Idec Pharmaceutical Corporation

patents

5. 1 out of 191

Seikagaku Corporation

patents

6. 1 out of 3,682

The Johns Hopkins University

patents

7. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1997-2013

Loading Chart...

25 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8603473 - Modified binding molecules comprising connecting peptides (2013-12-10),

2. 7744877 - Expression and use of anti-CD20 Antibodies (2010-06-29),

3. 7695940 - Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2010-04-13),

4. 7604989 - Inhibition of apoptosis process and improvement of cell performance (2009-10-20),

5. 7452534 - Recombinant anti-CD4 antibodies for human therapy (2008-11-18),

6. 7438906 - Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2008-10-21),

7. 7422739 - Anti-CD20 antibodies (2008-09-09),

8. 7381560 - Expression and use of anti-CD20 antibodies (2008-06-03),

9. 7338658 - Recombinant anti-CD4 antibodies for human therapy (2008-03-04),

10. 7332163 - Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2008-02-19),

11. 7223392 - Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2007-05-29),

12. 7033589 - γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2006-04-25),

13. 6893636 - Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics (2005-05-17),

14. 6682734 - Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma (2004-01-27),

15. 6399061 - Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma (2002-06-04),

Title: Inventor Mitchell E Reff - Revolutionizing Technology in San Diego

Introduction: Mitchell E Reff is a distinguished inventor based in San Diego, CA, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Mitchell E Reff holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Mitchell E Reff has worked with leading tech companies, research institutions, and universities to develop cutting-edge solutions that have had a significant impact on various industries.

Collaborations: Throughout his career, Mitchell E Reff has collaborated with top scientists, engineers, and inventors, fostering a culture of innovation and excellence in all his projects. His collaborative spirit has led to the creation of groundbreaking technologies that have shaped the future of multiple sectors.

Conclusion: Mitchell E Reff's passion for innovation, coupled with his dedication to pushing the boundaries of technology, has solidified his reputation as a visionary inventor in San Diego and beyond. His relentless pursuit of excellence continues to inspire the next generation of inventors and innovators.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent pending:

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.